Industry Verticals »

All Categories

Insights »

About TMR »

Myasthenia Gravis Market

Myasthenia Gravis Market (Treatment- Drug Treatment (Cholinesterase Inhibitors, Monoclonal Antibodies, and Chronic Immunomodulators) and Rapid Immunotherapies (Plasmapheresis, Intravenous Immunoglobulin (IVlg), and Thymectomy)) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

  • According to Transparency Market Research’s latest report on the global myasthenia gravis market for the historical period 2018–2019 and forecast period 2020–2030, high prevalence of autoimmune diseases and strong focus on introducing new therapies is augmenting the growth of global market. Moreover, improving healthcare infrastructure is likely boost the growth of market during the forecast period.
  • According to the report, the market was valued at US$ 1.2 Bn in 2018 and is anticipated to expand at a CAGR of 8.0% from 2019 to 2027
fa global myasthenia gravis market

Rise in Focus on Research & Development and Increase in Prevalence of Autoimmune Disorder: Key Drivers of Global Myasthenia Gravis Market

  • Autoimmune disorder is a condition of immune system in which the body's immune system attacks healthy cells. It is most common in the older men (over 60) and young adult women (under 40). Hence, increase in geriatric population is a key factor likely boost the growth of market. For instance, according to Cancer Facts & Figures 2019, estimated number of older adults age 85 years and above was 6.4 million in 2016 and it is expected to reach 19.0 million by 2060
  • Myasthenia gravis (MG) is an autoimmune neuromuscular disorder that affects voluntary muscles. According to the Myasthenia Gravis Foundation of America, around 20 in 100,000 people in the U.S. are diagnosed with myasthenia gravis each year
  • Myasthenia gravis is a rare disease without a definite cure, however it can be treated with medications, surgeries, and other therapies alone or in combination. This is augmenting the demand for new therapies and medications, which is driving key players operating in the market to invest in the research and development and develop new therapies. For instance, Rozanolixizumab (UCB7665) is a humanized anti-human neonatal Fc receptor (FcRn) monoclonal antibody designed to reduce the levels of pathogenic IgG in autoimmune diseases. It is in clinical trial phase for reducing the levels of pathogenic IgG in autoimmune diseases and myasthenia gravis. Strong pipeline and introduction of new therapies are the factors likely boost the growth of market

Increase in Healthcare Infrastructure Propel Global Myasthenia Gravis Market Growth

  • Increase in health care expenditure coupled with rise in global per capita income is anticipated to drive demand for costly treatments such as plasma exchange and intravenous immunoglobulin (IVIG) therapies
  • Moreover, governments in developing countries are making significant investments toward modernization of health care infrastructure, which is likely to increase access to health care. This is expected to increase in the demand for advance technologies, therapies and treatments. This is leading to create opportunities in the monoclonal antibodies and IVIG treatments in the market in the near future

Expensive Treatment Options to Hamper Global Myasthenia Gravis Market

  • Discovery and development of new therapeutics incurs high cost and takes longer time for commercialization. The never approved therapies with IVIG and monoclonal antibodies are expensive treatment options. The cost of plasma collection and manufacturing processes for IVIG products is high as compared to the materials and processes used in the manufacture of traditional pharmaceutical products. Moreover, being a blood derived component, highly sophisticated collection, purification, and storage methods are required for intravenous immunoglobulin (IVIG) products.
  • Plasmapheresis and thymectomy are costly in comparison to symptomatic drug therapy which additionally need hospitalization. Cost is major factor that influence the selection of treatment which is anticipated to hamper the growth of global myasthenia gravis treatment market.

Chronic Side Effects: Restrain of Global Myasthenia Gravis Market

  • Side effects associated with intravenous immunoglobulin (IVIG) preparations could present serious health problems in some patients. Some of the side effects associated with intravenous immunoglobulin (IVIG) are flushing, muscle cramps, chills, fever, nausea, vomiting, back/joint pain, chest pain, sudden cough, wheezing, or shortness of breath.
  • These side effects can sometimes force a patient to discontinue the therapy which are leading to restrain the global market.

Competitive Landscape

  • This report profiles major players in the global market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global myasthenia gravis market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global market are
    • Alexion Pharmaceutical Inc.
    • Avadel Pharmaceuticals, PLC. (Flamel Technologies)
    • CSL Behring
    • Grifols, S.A.
    • Baxter International, Inc.
    • Shire plc
    • Novartis AG
    • F. Hoffmann-La Roche AG
    • Takeda Pharmaceutical Company Limited
    • Valeant Pharmaceuticals International, Inc.

Key Developments

Key players in the global myasthenia gravis market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global market. A few expansion strategies adopted by players operating in the global market are:

  • In October 2019, Ra Pharmaceuticals Inc. and UCB entered into merger agreement in which UCB acquired Ra Pharma to enhanced the treatment option for the people living with myasthenia gravis and other rare diseases
  • In January 2018, Alexion’s Soliris launched with new myasthenia gravis indication
  • in October 2017, Alexion Pharmaceuticals, Inc. received the FDA approval for use of Solaris in the treatment of generalized myasthenia gravis

The report on the global myasthenia gravis market discussed individual strategies, followed by company profiles of manufacturers of myasthenia gravis. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global market.

Frequently Asked Questions

What is the total market worth of myasthenia gravis market?

Myasthenia gravis market is expected to reach US$ 2.4 Bn By 2027

What is the anticipated CAGR of the myasthenia gravis market in the forecast period?

Myasthenia gravis market is anticipated to expand at a CAGR of 8.0% from 2019 to 2027

What are the key driving factors for the growth of the myasthenia gravis market?

Myasthenia gravis market is driven by high prevalence of autoimmune diseases and strong focus on introducing new therapies

Which region is expected to project the highest market share in the global myasthenia gravis market?

North America accounted for major share of the global myasthenia gravis market and the trend is anticipated to continue during the forecast period

Who are the key players in the global myasthenia gravis market?

Key players in the global myasthenia gravis market include Alexion Pharmaceutical Inc., Avadel Pharmaceuticals, PLC. (Flamel Technologies), CSL Behring, Grifols, S.A.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Myasthenia Gravis Market 

4. Market Overview

    4.1. Introduction

        4.1.1. Treatment Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Myasthenia Gravis Market  Analysis and Forecasts, 2017–2027

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Key Industry Development (Acquisition, Collaboration, Merger, Approvals etc.)

    5.3. Epidemiology of Myasthenia Gravis By Country/Sub-region

    5.4. Regulatory Scenario

6. Global Myasthenia Gravis Market  Analysis and Forecasts, by Treatment Type

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Myasthenia Gravis Market Value & Volume Forecast by Treatment Type, 2017–2027

        6.2.1. Drug Treatment

            6.2.1.1. Cholinesterase Inhibitors

            6.2.1.2. Chronic Immunomodulators

            6.2.1.3. Monoclonal Antibodies

        6.2.2. Rapid Immunotherapies

            6.2.2.1. Plasmapheresis

            6.2.2.2. Intravenous Immunoglobulin (Ivlg)

        6.2.3. Thymectomy

    6.3. Global Myasthenia Gravis Market Attractiveness by Treatment Type

7. Global Myasthenia Gravis Market  Analysis and Forecasts, by Region

    7.1. Key Findings

    7.2. Global Myasthenia Gravis Market Value & Volume Forecast by Region

        7.2.1. North America 

        7.2.2. Europe 

        7.2.3. Asia Pacific 

        7.2.4. Latin America 

        7.2.5. Middle East & Africa 

    7.3. Global Myasthenia Gravis Market Attractiveness by Country/Region

8. North America Myasthenia Gravis Market  Analysis and Forecast

    8.1. Introduction

        8.1.1. Key Findings

    8.2.  North America Myasthenia Gravis Market Value & Volume Forecast by Treatment Type, 2017–2027

        8.2.1. Drug Treatment

            8.2.1.1. Cholinesterase Inhibitors

            8.2.1.2. Chronic Immunomodulators

            8.2.1.3. Monoclonal Antibodies

        8.2.2. Rapid Immunotherapies

            8.2.2.1. Plasmapheresis

            8.2.2.2. Intravenous Immunoglobulin (Ivlg)

        8.2.3. Thymectomy

    8.3. North America Myasthenia Gravis Market Value & Volume Forecast by Country, 2017–2027

        8.3.1. U.S.

        8.3.2. Canada

    8.4. North America Myasthenia Gravis Market Attractiveness Analysis 

        8.4.1. By Treatment Type

        8.4.2. By Country

9. Europe Myasthenia Gravis Market  Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Europe Myasthenia Gravis Market Value & Volume Forecast by Treatment Type, 2017–2027

        9.2.1. Drug Treatment

            9.2.1.1. Cholinesterase Inhibitors

            9.2.1.2. Chronic Immunomodulators

            9.2.1.3. Monoclonal Antibodies

        9.2.2. Rapid Immunotherapies

            9.2.2.1. Plasmapheresis

            9.2.2.2. Intravenous Immunoglobulin (Ivlg)

        9.2.3. Thymectomy

    9.3. Europe Myasthenia Gravis Market Value & Volume Forecast by Country/Sub-region, 2017–2027

        9.3.1. Germany

        9.3.2. U.K.

        9.3.3. France

        9.3.4. Spain

        9.3.5. Italy

        9.3.6. Rest of Europe

    9.4. Europe Myasthenia Gravis Market Attractiveness Analysis 

        9.4.1. By Treatment Type

        9.4.2. By Country/Sub-region

10. Asia Pacific Myasthenia Gravis Market  Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Asia Pacific Myasthenia Gravis Market Value & Volume Forecast by Treatment Type, 2017–2027

        10.2.1. Drug Treatment

            10.2.1.1. Cholinesterase Inhibitors

            10.2.1.2. Chronic Immunomodulators

            10.2.1.3. Monoclonal Antibodies

        10.2.2. Rapid Immunotherapies

            10.2.2.1. Plasmapheresis

            10.2.2.2. Intravenous Immunoglobulin (Ivlg)

        10.2.3. Thymectomy

    10.3. Asia Pacific Myasthenia Gravis Market Value & Volume Forecast by Country/Sub-region, 2017–2027

        10.3.1. China

        10.3.2. Japan

        10.3.3. India

        10.3.4. Australia & New Zealand

        10.3.5. Rest of Asia Pacific

    10.4. Asia Pacific Myasthenia Gravis Market Attractiveness Analysis 

        10.4.1. By Treatment Type

        10.4.2. By Country/Sub-region

11. Latin America Myasthenia Gravis Market  Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Latin America Myasthenia Gravis Market Value & Volume Forecast by Treatment Type, 2017–2027

        11.2.1. Drug Treatment

            11.2.1.1. Cholinesterase Inhibitors

            11.2.1.2. Chronic Immunomodulators

            11.2.1.3. Monoclonal Antibodies

        11.2.2. Rapid Immunotherapies

            11.2.2.1. Plasmapheresis

            11.2.2.2. Intravenous Immunoglobulin (Ivlg)

        11.2.3. Thymectomy

    11.3. Latin America Myasthenia Gravis Market Value & Volume Forecast by Country/Sub-region, 2017–2027

        11.3.1. Brazil

        11.3.2. Mexico

        11.3.3. Rest of Latin America

    11.4. Latin America Myasthenia Gravis Market Attractiveness Analysis 

        11.4.1. By Treatment Type

        11.4.2. By Country/Sub-region

12. Middle East & Africa Myasthenia Gravis Market  Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Middle East & Africa Myasthenia Gravis Market Value & Volume Forecast by Treatment Type, 2017–2027

        12.2.1. Drug Treatment

            12.2.1.1. Cholinesterase Inhibitors

            12.2.1.2. Chronic Immunomodulators

            12.2.1.3. Monoclonal Antibodies

        12.2.2. Rapid Immunotherapies

            12.2.2.1. Plasmapheresis

            12.2.2.2. Intravenous Immunoglobulin (Ivlg)

        12.2.3. Thymectomy

    12.3. Middle East & Africa Myasthenia Gravis Market Value & Volume Forecast by Country/Sub-region, 2017–2027

        12.3.1. GCC Countries

        12.3.2. South Africa

        12.3.3. Rest of Middle East & Africa

    12.4. Middle East & Africa Myasthenia Gravis Market Attractiveness Analysis 

        12.4.1. By Treatment Type

        12.4.2. By Country/Sub-region

13. Competition Landscape

    13.1. Market Player – Competition Matrix (By Tier and Size of companies)

    13.2. Market Share Analysis/Ranking By Company (2018)

    13.3. Company Profiles

        13.3.1. Alexion Pharmaceutical Inc. 

            13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.1.2. Growth Strategies

            13.3.1.3. SWOT Analysis. 

        13.3.2. Avadel Pharmaceuticals, PLC. (Flamel Technologies)

            13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.2.2. Growth Strategies

            13.3.2.3. SWOT Analysis. 

        13.3.3. CSL Behring 

            13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.3.2. Growth Strategies

            13.3.3.3. SWOT Analysis. 

        13.3.4. Grifols, S.A. 

            13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.4.2. Growth Strategies

            13.3.4.3. SWOT Analysis. 

        13.3.5. Baxter International, Inc. 

            13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.5.2. Growth Strategies

            13.3.5.3. SWOT Analysis. 

        13.3.6. Shire plc 

            13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.6.2. Growth Strategies

            13.3.6.3. SWOT Analysis. 

        13.3.7. Novartis AG 

            13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.7.2. Growth Strategies

            13.3.7.3. SWOT Analysis. 

        13.3.8. F. Hoffmann-La Roche AG

            13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.8.2. Growth Strategies

            13.3.8.3. SWOT Analysis. 

        13.3.9. Takeda Pharmaceutical Company Limited 

            13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.9.2. Growth Strategies

            13.3.9.3. SWOT Analysis. 

        13.3.10. Valeant Pharmaceuticals International, Inc.

            13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.10.2. Growth Strategies

            13.3.10.3. SWOT Analysis 

List of Table

Table 01: Global Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2017–2027

Table 02: Global Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment – Drug Treatment, 2017–2027

Table 03: Global Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment – Rapid Immunotherapies, 2017–2027

Table 04: Global Myasthenia Gravis Market Size (US$ Mn) Forecast, by Region, 2017–2027

Table 05: North America Myasthenia Gravis Market Size (US$ Mn) and Forecast, by Country, 2017–2027

Table 06: North America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2017–2027

Table 07: North America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Drug Treatment, 2017–2027

Table 08: North America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Rapid Immunotherapies, 2017–2027

Table 09: Europe Myasthenia Gravis Market Size (US$ Mn) Forecast, by Country, 2017–2027

Table 10: Europe Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2017–2027

Table 11: Europe Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment – Drug Treatment, 2017–2027

Table 12: Europe Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment – Rapid Immunotherapies, 2017–2027

Table 13: Asia Pacific Myasthenia Gravis Market Size (US$ Mn) and Forecast, by Country, 2017–2027

Table 14: Asia Pacific Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2017–2027

Table 15: Asia Pacific Myasthenia Gravis Market Size (US$ Mn) Forecast, by Drug Treatment, 2017–2027

Table 16: Asia Pacific Myasthenia Gravis Market Size (US$ Mn) Forecast, by Rapid Immunotherapies, 2017–2027

Table 17: Latin America Myasthenia Gravis Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017–2027

Table 18: Latin America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2017–2027

Table 19: Latin America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Drug Treatment, 2017–2027

Table 20: Latin America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Rapid Immunotherapies, 2017–2027

Table 21: Middle East & Africa Myasthenia Gravis Market Size (US$ Mn) and Forecast, by Country, 2017–2027

Table 22: Middle East & Africa Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2017–2027

Table 23: Middle East & Africa Myasthenia Gravis Market Size (US$ Mn) Forecast, by Drug Treatment, 2017–2027

Table 24: Middle East & Africa Myasthenia Gravis Market Size (US$ Mn) Forecast, by Rapid Immunotherapies, 2017–2027

List of Figure

Figure 01: Global Myasthenia Gravis Market Size (US$ Mn) Forecast, 2017–2027

Figure 02: Market Value Share By Region 

Figure 03: Market Value Share By Treatment 

Figure 04: Market Value Share By Rapid Immunotherapies 

Figure 05: Market Value Share By Drug Treatment 

Figure 06: Global Myasthenia Gravis Market Value Share Analysis, Treatment, 2018 and 2027

Figure 07: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, by Drug Treatment

Figure 08: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Rapid Immunotherapies

Figure 09: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Thymectomy

Figure 10: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Cholinesterase Inhibitors

Figure 11: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Chronic Immunomodulators

Figure 12: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Monoclonal Antibodies

Figure 13: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Plasmapheresis

Figure 14: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Intravenous Immunoglobulin

Figure 15: Global Myasthenia Gravis Market Attractiveness Analysis, by treatment, 2019–2027

Figure 16: Global Myasthenia Gravis Market Value Share Analysis, by Region, 2018 and 2027

Figure 17: Myasthenia Gravis Market Attractiveness Analysis, by Region

Figure 18: North America Myasthenia Gravis Market Size (US$ Mn) Forecast, 2017–2027

Figure 19: North America Myasthenia Gravis Market Attractiveness Analysis, by Treatment, 2019–2027

Figure 20: North America Myasthenia Gravis Market Attractiveness Analysis, by Country

Figure 21: North America Myasthenia Gravis Market Value Share Analysis, by Country, 2018 and 2027

Figure 22: North America Myasthenia Gravis Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 23: Europe Myasthenia Gravis Market Size (US$ Mn) Forecast, 2017–2027

Figure 24:  Europe Myasthenia Gravis Market Attractiveness Analysis, by Treatment, 2019–2027

Figure 25: Europe Myasthenia Gravis Market Attractiveness Analysis, by Country, 2019–2027

Figure 26: Europe Myasthenia Gravis Market Value Share Analysis, by Country, 2018 and 2027

Figure 27: Europe Myasthenia Gravis Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 28: Asia Pacific Myasthenia Gravis Market Size (US$ Mn) Forecast, 2017–2027

Figure 29: Asia Pacific Myasthenia Gravis Market Attractiveness Analysis, by Treatment, 2019–2027

Figure 30: Asia Pacific Myasthenia Gravis Market Attractiveness Analysis, by Country

Figure 31: Asia Pacific Myasthenia Gravis Market Value Share Analysis, by Country, 2018 and 2027

Figure 32: Asia Pacific Myasthenia Gravis Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 33: Latin America Myasthenia Gravis Market Size (US$ Mn) Forecast, 2017–2027

Figure 34: Latin America Myasthenia Gravis Market Attractiveness Analysis, by Treatment, 2019–2027

Figure 35: Latin America Myasthenia Gravis Market Attractiveness Analysis, by Country/Sub-region

Figure 36: Latin America Myasthenia Gravis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 37: Latin America Myasthenia Gravis Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 38: Middle East & Africa Myasthenia Gravis Market Size (US$ Mn) Forecast, 2017–2027

Figure 39:  Middle East & Africa Myasthenia Gravis Market Attractiveness Analysis, by Treatment, 2019–2027

Figure 40: Middle East & Africa Myasthenia Gravis Market Attractiveness Analysis, by Country

Figure 41: Middle East & Africa Myasthenia Gravis Market Value Share Analysis, by Country, 2018 and 2027

Figure 42: Middle East & Africa Myasthenia Gravis Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 43: Alexion Pharmaceutical Inc. Revenue (US$ Mn) & Y-o-Y Growth (%)

Figure 44: Alexion Pharmaceutical Inc. Research & Development Expenses

Figure 45: Alexion Pharmaceutical Inc. Breakdown of Net Sales, by Product

Figure 46: Alexion Pharmaceutical Inc. Breakdown of Net Sales, by Region

Figure 47: AVADEL PHARMACEUTICALS, PLC. Revenue (US$ Mn) & Y-o-Y Growth (%)

Figure 48: AVADEL PHARMACEUTICALS, PLC. Long-lived Assets (US$ Mn), by Geographic Region

Figure 49: AVADEL PHARMACEUTICALS, PLC. Breakdown of Net Sales, by Product

Figure 50: AVADEL PHARMACEUTICALS, PLC. Net Sales, by Region

Figure 51: CSL Behring Revenue (US$ Mn) & Y-o-Y Growth (%)

Figure 52: CSL Behring Research & Development Expenses

Figure 53: CSL Behring Breakdown of Net Sales, by Product

Figure 54: CSL Behring Breakdown of Net Sales, by Region

Figure 55: Grifols, S.A. Revenue (US$ Mn) & Y-o-Y Growth (%)

Figure 56: Grifols, S.A. Research & Development Expenses

Figure 57: Grifols, S.A. Breakdown of Net Sales, by Business Segment

Figure 58: Grifols, S.A. Breakdown of Net Sales, by Region

Figure 59: Baxter International, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%)

Figure 60: Baxter International, Inc. Marketing and R&D Expenses

Figure 61: Baxter International, Inc. Breakdown of Net Sales, by Product

Figure 62: Baxter International, Inc. Breakdown of Net Sales, by Region

Figure 63: Shire plc Revenue (US$ Mn) and Y-o-Y Growth (%)

Figure 64: Shire plc R&D and Marketing Expenses

Figure 65: Shire plc Breakdown of Net Sales, by Product

Figure 66: Shire plc Breakdown of Net Sales, by Region

Figure 67: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%)

Figure 68: Novartis AG Marketing & Sales, and R&D Expenses

Figure 69: Novartis AG Breakdown of Net Sales, by Business Segment

Figure 70: Novartis AG Breakdown of Net Sales, by Region

Figure 71: F. Hoffmann-La Roche AG Revenue (US$ Bn) and Y-o-Y Growth (%)

Figure 72: F. Hoffmann-La Roche AG Marketing and R&D Expenses

Figure 73: F. Hoffmann-La Roche AG Breakdown of Net Sales, by Business Division

Figure 74: F. Hoffmann-La Roche AG Breakdown of Net Sales, by Region

Figure 75: Takeda Pharmaceutical Company Limited Revenue (US$ Bn) and Y-o-Y Growth (%)

Figure 76: Takeda Pharmaceutical Company Limited Research And Development Expenses

Figure 77: Takeda Pharmaceutical Company Limited Breakdown of Net Sales, by Business Segment

Figure 78: Takeda Pharmaceutical Company Limited Breakdown of Net Sales, by Region

Figure 79: Valeant Pharmaceuticals International, Inc Revenue (US$ Bn) and Y-o-Y Growth (%)

Figure 80: Valeant Pharmaceuticals International, Inc Marketing and R&D Expenses

Figure 81: Valeant Pharmaceuticals International, Inc Breakdown of Net Sales, by Region

Figure 82: Valeant Pharmaceuticals International, Inc Breakdown of Net Sales, by Business Segment

Copyright © Transparency Market Research, Inc. All Rights reserved

Myasthenia Gravis Market

Schedule a Call